- 20,000-square-foot site increases Endo’s sterile injectable production capacity
- This marks the site’s first U.S. FDA approval
- Endo is investing and innovating in its Injectable Solutions business
MALVERN, Pa., Dec. 9, 2024 /PRNewswire/ — Endo, Inc. (OTCQX: NDOI) announced today that the U.S. Food and Drug Administration (FDA) has approved commercial production of VASOSTRICT® (vasopressin injection, USP) at the company’s newest aseptic manufacturing facility in Indore, India. The 20,000-square-foot site increases Endo’s sterile injectable production capacity and expands the future growth potential for its Injectable Solutions business.
“This is a significant milestone for Endo as we invest and innovate in our sterile injectables business,” said Scott Hirsch, Interim CEO of Endo. “The FDA approval of our newest manufacturing site demonstrates our commitment to meeting product demand and delivering quality medicines to patients.”
The Indore facility is designed specifically for aseptic manufacturing of sterile injectable products—a difficult and highly specialized production capability. The site is expected to eventually produce medicines in syringes, in addition to vials. Read More >
